AI Engines For more Details: Perplexity Kagi Labs You
Mood Regulation: Serotonin is often referred to as the "feel-good" neurotransmitter because it contributes to feelings of well-being and happiness. Medications that increase serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), are commonly used to treat depression, anxiety disorders, and certain mood disorders.
Appetite and Weight Regulation: Serotonin plays a role in regulating appetite and food intake. Medications that affect serotonin levels may help in managing weight by influencing feelings of satiety and reducing food cravings.
Sleep Regulation: Serotonin is involved in the regulation of sleep-wake cycles and the promotion of restful sleep. Drugs that affect serotonin levels may be used to treat sleep disorders such as insomnia.
Gastrointestinal Function: Serotonin has a significant impact on gastrointestinal function, including regulating intestinal motility, secretion, and sensation. Medications that target serotonin receptors in the gut may be used to manage gastrointestinal disorders such as irritable bowel syndrome (IBS) and functional dyspepsia.
Pain Perception: Serotonin is involved in modulating pain perception and processing. Some medications that affect serotonin levels may have analgesic effects and can be used to manage certain types of pain.
Cardiovascular Function: Serotonin is involved in regulating cardiovascular function, including blood pressure, heart rate, and blood clotting. However, the effects of serotonin hydrochloride on cardiovascular function are complex and may vary depending on the specific context and dosage.
Mental Health Disorders: Imbalances in serotonin levels have been implicated in various mental health disorders, including depression, anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). Medications that target serotonin neurotransmission are often used as part of the treatment for these conditions.
Neurotransmitter Regulation: Serotonin interacts with other neurotransmitter systems in the brain, including dopamine and norepinephrine. Modulating serotonin levels can influence the activity of these neurotransmitters, which can have wide-ranging effects on mood, cognition, and behavior.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.1 | 0.1 | |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | |
| Allergies | 0.7 | 0.7 | |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 0.3 | 0.3 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.5 | |
| Ankylosing spondylitis | 0.3 | 0.1 | 2 |
| Anorexia Nervosa | 0.2 | -0.2 | |
| Atrial fibrillation | 0.5 | 0.5 | |
| Autism | 0.3 | 0.8 | -1.67 |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.4 | -0.4 | |
| Chronic Fatigue Syndrome | 0.2 | 1 | -4 |
| Chronic Kidney Disease | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | -0.1 | |
| Colorectal Cancer | 0.1 | -0.1 | |
| Constipation | 0.1 | 0.1 | |
| Coronary artery disease | 0.1 | 0.1 | |
| COVID-19 | 0.7 | 1.4 | -1 |
| Crohn's Disease | 0.3 | 0.8 | -1.67 |
| Depression | 0.5 | 0.3 | 0.67 |
| Endometriosis | 0.3 | 0.1 | 2 |
| Fibromyalgia | 0.3 | 0.3 | |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.1 | |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Graves' disease | 0.3 | -0.3 | |
| Hashimoto's thyroiditis | 0.3 | 0.3 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.1 | 1 |
| IgA nephropathy (IgAN) | 0.2 | -0.2 | |
| Inflammatory Bowel Disease | 0.3 | -0.3 | |
| Insomnia | 0.1 | -0.1 | |
| Irritable Bowel Syndrome | 0.1 | -0.1 | |
| Liver Cirrhosis | 0.3 | 0.3 | 0 |
| Long COVID | 0.2 | 0.7 | -2.5 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.7 | -0.7 | |
| ME/CFS without IBS | 0.1 | 1 | -9 |
| Metabolic Syndrome | 0.3 | 0.3 | 0 |
| Mood Disorders | 0.5 | 0.3 | 0.67 |
| Multiple Sclerosis | 0.3 | 0.4 | -0.33 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.3 | 0 |
| Obesity | 1 | 0.4 | 1.5 |
| obsessive-compulsive disorder | 0.1 | 0.4 | -3 |
| Parkinson's Disease | 0.2 | -0.2 | |
| primary biliary cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.7 | 0.7 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 0.3 | 0.33 |
| Schizophrenia | 0.1 | 0.1 | |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 0.4 | -0.4 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | |
| Systemic Lupus Erythematosus | 0.1 | -0.1 | |
| Tic Disorder | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.1 | -0.1 | |
| Type 2 Diabetes | 0.3 | 0.3 | 0 |
| Ulcerative colitis | 0.4 | 0.4 | |
| Unhealthy Ageing | 0.2 | -0.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.